Autoimmune Diseases Working Party (ADWP)
Study type:
Study number:
8410016
Type of Stem Cell Treatment:
Autologous
Diseases:
Auto immune disorders
Short title:
OMST
Primary objective:
To gain further homogenous evidence for clinical efficacy of aHSCT in patients undergoing aHSCT for MS as primary indication.
Key inclusion criteria:
• Diagnosis of MS according to McDonald’s criteria
• Availability of a detailed clinical history about MS, including progression of disability and relapse rate in the previous 2 years, treatments administered before aHSCT, and categorization of the sub-types of MS according to current EBMT guidelines20
o Highly active relapsing remitting MS failing DMTs
o Progressive MS with active inflammatory component. In accordance with the EBMT guidelines, this category includes both secondary and primary progressive MS with active inflammatory component.
o Aggressive (malignant) MS not previously treated with a full course of DMT
• Patients aged 18 or over at time of first aHSCT
• Signed informed consent
• Availability of a detailed clinical history about MS, including progression of disability and relapse rate in the previous 2 years, treatments administered before aHSCT, and categorization of the sub-types of MS according to current EBMT guidelines20
o Highly active relapsing remitting MS failing DMTs
o Progressive MS with active inflammatory component. In accordance with the EBMT guidelines, this category includes both secondary and primary progressive MS with active inflammatory component.
o Aggressive (malignant) MS not previously treated with a full course of DMT
• Patients aged 18 or over at time of first aHSCT
• Signed informed consent
Country:
Principal investigator:
Riccardo Saccardi
EBMT Study coordinator:
Manuela Badoglio
Study coordinator email:
manuela.badoglio@upmc.fr